Specialized, state-of-the-art clinical research unit established in 2003 in Southern California and globally recognized for metabolic drug and device clinical trials.
- First-in-Human, First-in-Patient studies
- Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) studies
- Proof of Concept (PoC), Proof of Mechanism (PoM), Mechanism of Action (MoA) studies
- Bioequivalence and drug/drug interaction studies
- Full spectrum of automated glucose clamp studies
- 21,000 sq ft and 30+ treatment beds
- Eight-week in-patient extended stay capabilities
- CLIA-certified laboratory
- USP 797/800 standard clean room
- 24/7 on-site medical and clinical teams